资讯

Taiwan News7 天
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate ...
As a result, we are terminating all ongoing oncology trials involving icovamenib and will conclude the BMF-500 study in patients with relapsed/refractory acute leukemia with FLT3 gene mutations ...
Morningstar8 天
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate ...
As a result, we are terminating all ongoing oncology trials involving icovamenib and will conclude the BMF-500 study in patients with relapsed/refractory acute leukemia with FLT3 gene mutations ...